NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working...

|By:, SA News Editor

NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working capital, including research and development of cell therapeutic product candidates, including AMR-001, plus expansion of its business units, strategic transactions and other general corporate purposes. Terms and size of the offering have not yet been disclosed. Aegis Capital is acting as sole book-running manager. Shares -8% AH.